clemastine / Generic mfg. - LARVOL DELTA

Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study. (PubMed, JCO Oncol Pract) - "Premedication containing oral cetirizine is as safe as premedication containing intravenous clemastine in preventing paclitaxel-induced HSR grade ≥3. These findings could contribute to optimization of care for patients and improve efficiency and sustainability."

Journal • Immunology

Developmental Deficiency of Oligodendrocytes and Myelination in the Central Nervous System of the Fetal Alcohol Syndrome Mouse Model. (PubMed, CNS Neurosci Ther) - "Our data reveal a gender-related deficiency of CNS myelination in the FASD mouse model, suggesting a potential therapy target for FASD."

Journal • Preclinical • Solid Tumor • CDKN1A • GFAP

Establishment of H1R-SNAP-tag/CMC and screening for anti-allergic active ingredients targeting H1R. (PubMed, Anal Bioanal Chem) - "The H1R-SNAP-tag/CMC-HPLC-MS system was investigated using the H1R antagonist Clemastine fumarate and the results showed that the system was a reliable model for screening potential anti-allergic compounds from TCMs...tectorum) extract, six H1R-binding compounds were identified: tectoridin, iristectorin A, iridin, tectorigenin, irigenin, and irisflorentin. Frontal analysis and molecular docking confirmed their affinity for H1R, while subsequent in vivo and in vitro pharmacological assays preliminarily validated their anti-allergic efficacy."

Journal • Allergy

Peripheral Nerve Injury and Denervation-Induced Sarcopenia with a Focus on Pharmacological Dual-Target Strategies. (PubMed, Biomol Ther (Seoul)) - "We focus on agents such as 4-aminopyridine (4-AP), a potassium channel blocker that enhances nerve conduction, and clemastine, an antihistamine that promotes Schwann cell-mediated remyelination. Additionally, we highlight the critical crosstalk between motor neurons and skeletal muscle, mediated by neurotrophic factors such as brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and Neurotrophin-3 (NT-3), which support both neuromuscular junction stability and axonal regrowth. By integrating insights from nerve biology and muscle physiology, this review outlines a therapeutic framework that targets both nerve regeneration and muscle preservation, an approach that effectively addresses nerve injury-induced sarcopenia effectively."

Journal • Review • Metabolic Disorders • Sarcopenia • Targeted Protein Degradation • NTF3 • STAT3 • TGFB1

An Adaptive, Time-Informed, Phenotype-Guided Pharmacological Framework for Severe Traumatic Brain Injury : A Hypothesis-Driven Narrative Review. (PubMed, J Korean Neurosurg Soc) - "Glibenclamide/glyburide and hypertonic sodium lactate produced preliminary imaging or physiological signals without demonstrated functional benefit. Riluzole was neutral in an adult randomized trial, whereas a small study in chronic TBI found that minocycline reduced a neuroinflammatory imaging signal but increased plasma neurofilament light. Metformin and N-acetylcysteine plus probenecid provided exploratory pharmacokinetic, biomarker, or safety data. Amantadine provided phenotype-specific clinical proof of principle in traumatic disorders of consciousness. Cerebrolysin showed mixed human evidence, including a favorable day-90 multidimensional ensemble signal that requires independent replication. Deferoxamine and clemastine remain preclinical...Module activation should require optimized foundational care, a matching phenotype, measurable target activation or engagement, and acceptable systemic safety. This framework prioritizes phenotype-enriched, single-module..."

Journal • CNS Disorders • Vascular Neurology • Plasma NfL

Effects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine. (PubMed, Purinergic Signal) - "First, in murine and human cells expressing (B16F10 WT and HEK293-hP2X7) or lacking (B16F10 P2X7-/- and HEK293 WT) the P2X7 receptor, we measured intracellular Ca2+ influx, ethidium bromide (EB) and daunorubicin (DN) uptake, mitochondrial morphology, and LDH and ATP release following P2X7 agonism or antagonism in the presence of CLE. We found that the combined treatment significantly increased IL-1β release from P2X7-WT macrophages compared to the two stimuli administered separately. On the whole, our results demonstrate that CLE can effectively positively modulate P2X7 function, suggesting new opportunities for its therapeutic exploitation."

Journal • Preclinical • Allergic Rhinitis • Immunology • Melanoma • Oncology • Solid Tumor • IL1B • NLRP3

Combined clemastine fumarate and selenomethionine promote remyelination via PI3K/Akt/mTOR signaling in experimental multiple sclerosis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Treatment was further associated with normalization of altered PI3K, Akt, and mTOR protein expression and substantial preservation of myelin integrity. CMF and SLM thus appear to exert complementary neuroprotective and remyelinating effects, CMF principally promoting oligodendrocyte-mediated remyelination and SLM limiting oxidative and inflammatory injury that together converge on the PI3K/Akt/mTOR axis, supporting simultaneous dual-target intervention as a rational strategy for MS."

Journal • CNS Disorders • Cognitive Disorders • Inflammation • Multiple Sclerosis • Solid Tumor • mTOR

Hippocampal teneurin-4 knockdown promotes depression-like behavioral phenotypes by disrupting oligodendrocyte differentiation in mice. (PubMed, Neuropharmacology) - "Importantly, administration of clemastine, a myelin formation promoter, inhibited the reduction of myelin and attenuated depression-like behavioral phenotypes...This study provides the first evidence that hippocampal Tenm4 deficiency induces depression-like behavior phenotypes through impaired oligodendrocyte differentiation and promoting demyelination. Our results identify Tenm4 as a molecular regulator of stress-induced behavioral phenotypes and suggest that it might represent a potential therapeutic target for mood disorders associated with demyelination."

Journal • Preclinical • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • Solid Tumor • MBP • TENM4

Enhancing Oligodendrogenesis Rescues Chronic Stress-Induced Behavioral Disorders Involving Neuronal and Synaptic Reorganization. (PubMed, Glia) - "Importantly, treating the stressed animal with the pro-myelination drug clemastine phenocopied the effects of M1R deletion on histological and behavioral disorders. Together, our findings demonstrate that enhancing oligodendrogenesis represents a promising strategy to rescue CRS-caused behavioral disorders."

Journal • Behavior Disorders • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • Solid Tumor • FOS • OLIG2

Neonatal White Matter Injury Trial (WRAP) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Bridget LaMonica Ostrem, M.D., Ph.D. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Vascular Neurology

Carboplatin induces optic nerve oligodendrocyte loss and impairs myelin sheath microstructure in a mouse model of neurofibromatosis type 1 (NF1). (PubMed, Neuro Oncol) - "Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure."

Journal • Preclinical • Brain Cancer • Genetic Disorders • Glioma • Neurofibromatosis • Oncology • Solid Tumor • NF1

Neonatal White Matter Injury Trial (WRAP) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Bridget LaMonica Ostrem, M.D., Ph.D.

New P1 trial • CNS Disorders • Vascular Neurology

Panax quinquefolius saponins promote remyelination via orchestrating HMGCS1-NPC1-MAL-mediated lipid metabolism and rebalancing JAK-STAT signaling in a cuprizone-induced demyelination model. (PubMed, J Ethnopharmacol) - "PQS supported myelin restoration, which is correlated with a modulation of the JAK-STAT signaling pathway and HMGCS1/NPC1-associated lipid homeostasis. PQS may represent a potential therapeutic lead for demyelinating diseases, although mechanisms require further validation."

Journal • CNS Disorders • Metabolic Disorders • Multiple Sclerosis • HMGCS1 • JAK1 • NLRP3 • PLIN2

The Potential of Rehabilitation to Amplify Experience-Induced Myelin Plasticity and Remyelination in Multiple Sclerosis: A Narrative Review. (PubMed, Curr Neurol Neurosci Rep) - "Notably, the combination of exercise and clemastine produces robust remyelination in preclinical models...Motor learning, physical exercise, and multimodal interventions may support adaptive myelination, though optimized dosing, timing, and biomarkers remain undefined. Future research should employ targeted, multimodal imaging approaches and integrate behavioral, neuromodulatory, and pharmacologic strategies, in addition to following patients longitudinally post-intervention, to clarify the therapeutic potential of activity-driven remyelination."

Journal • Review • CNS Disorders • Inflammation • Multiple Sclerosis • Solid Tumor

ReVIVE: Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy (clinicaltrials.gov) - P1/2 | N=74 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease. (PubMed, Basic Clin Pharmacol Toxicol) - "Proton pump inhibitors (PPIs), opioids and non-benzodiazepine hypnotics (Z-drugs) were identified as common PIMs, whereas bladder antimuscarinics (tolterodine and solifenacin), sedating antihistamines (clemastine and promethazine) and antipsychotics with anticholinergic properties (quetiapine) were the most frequently used medications with strong anticholinergic properties. In conclusion, medication burden in patients with CKD is high, and incorporating PIMs and ACB scores may identify prescribing risks not captured by medication counts alone."

Journal • Retrospective data • Chronic Kidney Disease • CNS Disorders • Nephrology • Renal Disease

Clemastine as remyelinating treatment in patients with multiple sclerosis and internuclear ophthalmoplegia (EAN 2026) - "Background and aims: Remyelination failure contributes to disability and disease progression in multiple sclerosis (MS). Inclusion of people with INO expands on previous studies on optic neuropathy and provides a platform to study central nervous system remyelination within the brainstem. Selecting for likely remyelinators through fampridine response is feasible and may strengthen future remyelination trials. Monday, June 29 2026 Late-breaking ePoster Session"

Clinical • Late-breaking abstract • CNS Disorders • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

CLIMB: Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: University of Illinois at Chicago | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Clemastine ameliorates ulcerative colitis-induced cognitive impairment by restoring PI3K/Akt/GSK-3β signaling and suppressing ferroptosis. (PubMed, Inflammopharmacology) - "Importantly, by crossing the BBB, clemastine could exert additional anti-inflammatory and neuroprotective effects by affecting the central assessed pathways. In conclusion, these findings clarify the pivotal role of clemastine in the management of colonic inflammation-associated cognitive decline through modulating multiple and interacting peripheral and central pathways to provide its potent neuroprotection."

Journal • Alzheimer's Disease • Cognitive Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CASP3 • CLDN1 • GPX4 • GSK3B • IL1B • TNFA

Clemastine alleviates cognitive dysfunction after SAH by targeting neuronal CNTN1 to regulate the ADA-adenosine pathway. (PubMed, Acta Pharmacol Sin) - "Its downregulation exacerbates demyelination through ADA after SAH. Importantly, clemastine might be potential drug used in SAH patients."

Journal • Alzheimer's Disease • Cognitive Disorders • Hematological Disorders • Solid Tumor • Subarachnoid Hemorrhage • ADORA2B • CNTN • CNTN1 • PLP1

Letter to the Editor: Evaluation of Clemastine's Effects on Clinical and Electrodiagnostic Parameters in Individuals With CTS: A Preliminary Placebo-Controlled Double-Blind RCT. (PubMed, Arch Rehabil Res Clin Transl) - No abstract available

Journal

Neuroinflammation mediated repurposing of clemastine for Alzheimer's disease through network pharmacology, molecular dynamics, and experimental validation studies. (PubMed, Inflammopharmacology) - "The study provides novel integrative evidence linking its antihistaminic action with simultaneous regulation of neuroinflammation through multi-target modulation of inflammation, oxidative stress, and neuronal signaling pathways, highlighting its potential as a promising repurposed therapeutic candidate for AD."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • Pain • DRD2 • IL1B • NLRP3 • SLC6A4 • TNFA

Occupational Anaphylaxis to Piperacillin-Tazobactam in a Nurse: A Case Report. (PubMed, J Investig Med High Impact Case Rep) - "We report the case of a 26-year-old female nurse with persistent atopic dermatitis and previous history of allergic contact dermatitis to nickel and cobalt, who developed occupational anaphylaxis while preparing intravenous cefuroxime and piperacillin-tazobactam. She presented with acute erythematous papules, rhinorrhea, wheezing, dyspnea, and tachycardia, requiring treatment with intramuscular epinephrine, intravenous clemastine, and hydrocortisone, with complete clinical resolution...Additional work-up showed positive specific IgE to penicilloyl G and amoxicillin, with negative latex and formaldehyde testing and normal baseline tryptase...In selected cases transfer to a low-exposure work environment may be required. This case reinforces that non-therapeutic occupational exposure to piperacillin-tazobactam can lead to life-threatening IgE-mediated anaphylaxis, highlighting the need for increased awareness and structured preventive strategies in healthcare settings."

Journal • Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • Pulmonary Disease

Acute Generalized Exanthematous Pustulosis Triggered by H. pylori Eradication Therapy: A Case Report (EADV-Sp 2026) - "Materials and Methods We report a case of a 67-year-old female who developed an AGEP after initiating triple therapy for H. pylori eradication (amoxicillin, clarithromycin, pantoprazole)...Previous outpatient treatment with clemastine and intramuscular dexamethasone was ineffective...Due to disseminated lesions, systemic treatment with oral prednisolone 30 mg/day was initiated for 5 days with a gradual taper...Alternative options were suggested, including cefuroxime, third- or fourth-generation cephalosporins, while macrolides should be avoided...Early recognition, prompt withdrawal of potential offending agents, and histopathologic confirmation remain essential for favorable outcomes. Systematic and comprehensive evaluation, including allergological testing, is essential to identify potential triggers and guide the safe selection of future therapeutic options for affected patients."

Case report • Clinical • Eosinophilia • Immunology • Pruritus • CRP

RESTORE: Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis (clinicaltrials.gov) - P3 | N=47 | Terminated | Sponsor: Amsterdam UMC, location VUmc | N=80 ➔ 47 | Trial completion date: Dec 2027 ➔ Aug 2025 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2027 ➔ Aug 2025; In line with the study protocol, due to slow recruitment, a futility analysis has been performed in the first quarter of 2025 by an independent statistician. The result of the analysis was restricted to a "no-go".

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Multiple Sclerosis • Ophthalmology